Major Events in the FDA Pipeline During COVID-19

0
212

Pharmacy Times spoke to Chad Landmon, attorney and chairman of Axinn’s Intellectual Property and FDA Practice Groups, about key events in the FDA pipeline, such as emergency clearances during COVID-19 and the future of restricted approvals.

Pharmacy Times spoke to Chad Landmon, attorney and chairman of Axinn’s Intellectual Property and FDA Practice Groups, about key events in the FDA pipeline, such as emergency clearances during COVID-19 and the future of restricted approvals.

Landmon also discussed the most recent emergency approvals, which must be highlighted in the pipeline, and the impact of “thin labels” on generic drugs in the marketplace.